Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ALPELISIB vs ALPROSTADIL: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ALPELISIB vs ALPROSTADIL: Safety Overview

Metric ALPELISIB ALPROSTADIL
Total FAERS Reports 8,419 2,800
Deaths Reported 1,271 60
Death Rate 15.1% 2.1%
Hospitalizations 1,705 210
Average Patient Age 58.8 yrs 62.5 yrs
% Female Patients 94.7% 4.9%
FDA Approval Date Apr 24, 2024 Approved Prior to Jan 1, 1982
Manufacturer Novartis Pharmaceuticals Corporation ENDO USA, Inc.
Route ORAL INTRACAVERNOUS
Marketing Status Prescription Prescription